Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Urologix

This article was originally published in The Gray Sheet

Executive Summary

Expanded labeling approval for the Targis system includes a claim for treatment of the obstruction in the urethra caused by benign prostatic hyperplasia, the firm reports Aug. 7. No similar devices have been approved for this indication, the firm states. The system is currently approved for treatment BPH symptoms, such as frequent urination. Separately, the company reports revenues of $11.2 mil. for fiscal year 1998 ending June 30 compared to $5.5 mil. one year ago. Urologix books a larger net loss in FY 1998 ($15 mil.) versus its net loss in the year prior period ($8.2 mil.)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010484

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel